Revenues rise three-fold at Fusion Antibodies
BELFAST-based clinical research firm Fusion Antibodies saw its revenues rise three-fold in the six months to September 30.
The company's latest half year report showed revenues rose to £1.75m, up from £0.66m in the first half of last year. However the company continued to post a loss of £470,000, albeit down on the £740,000 recorded in the same period last year.
Chief Executive of the publicly listed firm, Paul Kerr, said: “Our revenues are growing apace, and we have seen a solid improvement in the performance of the business for this period, compared to the previous six months.
“We are on target to deliver significant revenue growth year on year and, as always, I would like to thank our shareholders and staff for all their valued support.”